Alx Oncology Holdings (ALXO) Assets (2019 - 2026)
Alx Oncology Holdings recorded quarterly Assets of $178.3 million in Q1 2026, up 202.02% quarter-over-quarter from $59.0 million in Q4 2025, and up 47.5% year-over-year from $120.9 million in Q1 2025.
Alx Oncology Holdings' Assets history runs 8 years deep, the most recent figure standing at $178.3 million for Q1 2026.
- In Q1 2026, Assets rose 47.5% year-over-year to $178.3 million; the TTM figure through Mar 2026 stood at $178.3 million (up 47.5% YoY), while the FY2025 annual figure was $59.0 million, down 60.04% from the prior year.
- Assets came in at $178.3 million for Q1 2026 at Alx Oncology Holdings, up from $59.0 million in the prior quarter.
- In the past five years, Assets ranged from a high of $363.7 million in Q1 2022 to a low of $59.0 million in Q4 2025.
- A 5-year average of $212.8 million and a median of $214.6 million in 2024 frame the typical range for Assets.
- Across the five-year window, Assets slumped 60.04% in 2025 and soared 47.5% in 2026, its largest moves.
- Alx Oncology Holdings' Assets stood at $306.5 million in 2022, then decreased by 20.86% to $242.6 million in 2023, then tumbled by 39.08% to $147.8 million in 2024, then plunged by 60.04% to $59.0 million in 2025, then soared by 202.02% to $178.3 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $178.3 million, $59.0 million, and $82.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | 178.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 178.33 Mn |
| Dec 31, 2025 | 59.05 Mn |
| Sep 30, 2025 | 82.72 Mn |
| Jun 30, 2025 | 95.32 Mn |
| Mar 31, 2025 | 120.90 Mn |
| Dec 31, 2024 | 147.78 Mn |
| Sep 30, 2024 | 185.72 Mn |
| Jun 30, 2024 | 214.62 Mn |
| Mar 31, 2024 | 212.65 Mn |
| Dec 31, 2023 | 242.55 Mn |
| Sep 30, 2023 | 220.11 Mn |
| Jun 30, 2023 | 245.93 Mn |
| Mar 31, 2023 | 278.14 Mn |
| Dec 31, 2022 | 306.49 Mn |
| Sep 30, 2022 | 317.69 Mn |
| Jun 30, 2022 | 346.02 Mn |
| Mar 31, 2022 | 363.68 Mn |
| Dec 31, 2021 | 380.18 Mn |
| Sep 30, 2021 | 399.73 Mn |
| Jun 30, 2021 | 421.29 Mn |
| Mar 31, 2021 | 432.91 Mn |
| Dec 31, 2020 | 436.05 Mn |
| Sep 30, 2020 | 262.45 Mn |
| Jun 30, 2020 | 103.11 Mn |
| Dec 31, 2019 | 10.68 Mn |